We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
167 result(s) found, displaying 91 to 100
-
Cancellation by sponsorRequested by Novo Nordisk Pharmaceuticals Pty Ltd
-
Cancellation by sponsorRequested by Novo Nordisk Pharmaceuticals Pty Ltd
-
Cancellation by sponsorRequested by Novo Nordisk Pharmaceuticals Pty Ltd
-
Cancellation by sponsorRequested by Novo Nordisk Pharmaceuticals Pty Ltd
-
Cancellation by sponsorRequested by Novo Nordisk Pharmaceuticals Pty Ltd
-
Cancellation by sponsorRequested by Novo Nordisk Pharmaceuticals Pty Ltd
-
Prescription medicine registrationActive ingredients: insulin degludec; liraglutide.
-
Australian public assessment report (AusPar)Ozempic (semaglutide) has been approved for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
-
Australian public assessment report (AusPar)New AusPAR for Fiasp, Fiasp Penfill, Fiasp FlexTouch (insulin aspart rys) for the treatment of diabetes mellitus
-
Section 14, TGO91 consentProduct(s) approved for Supply with noncompliant labelling.